Dr. Birgit Ritter
Dr. Birgit Ritter studied biology at the Friedrich-Schiller University in Jena. In 2010 she started her PhD in the lab of Falk Nimmerjahn at the University of Erlangen, investigating the role of effector cells in antibody-dependent melanoma therapy. After continuing as a postdoc to work on antibody therapy in colitis, she joined the Greten lab in 2016 as a staff scientist. Here, she is entrusted with the human CRC biobank, scientific coordination and writing of regulatory applications. Since 2018 she has also been head of our histology department.
Eva received her training as a medical technical assistant in 1999 in Würzburg and joined the Georg-Speyer-Haus in 2005.
Dr. Valentina Petrocelli
Dr. Valentina Petrocelli studied genetics and molecular oncology at the University Sapienza (Italy). In 2012 she started the PhD in molecular medicine at the European School of Molecular Medicine, working in the laboratory of Dr. Stefano Casola at the FIRC IFOM - Institute of Molecular Oncology in Milan (Italy). She was involved in dissecting the role of epigenetic modifiers in B lymphocyte development and lymphoma transformation. Graduated in March 2016, she continued as Postdoc in the same lab. Valentina joined the Greten lab in September 2018 to study the contribution of immune cells to colon cancer biology.
Dr. Marina Pešić
Dr. Marina Pešić graduated at University of Belgrade (Serbia), Faculty of Biology in 2007. During her diploma thesis she worked in Prof. Jelena Milasin’s laboratory of Cytogenetics and Molecular Genetics, Institute of Biology and Human Genetics, School of Dentistry, University of Belgrade (Serbia). In 2008, she started PhD in Prof. Lars Zender’s group at the Helmholtz Centre for Infection Research in Braunschweig before moving with the group to University Hospital Tübingen. During her PhD work she was applying RNAi based functional genetic and genomic approaches to study liver cancer and liver regeneration. She was involved in the development of transposon based stable shRNA technology that can be used to conduct pooled shRNA screens directly in vivo. She joined the Greten lab as a Postdoc in 2014. She is currently working on the functional identification of new modulators of metastasis in colon cancer.
Dr. Charles Pallangyo
Dr. Charles Pallangyo trained as an MD at MUHAS in Daressalam (Tanzania). He then got his PhD in Florian Greten’s lab studying the role of fibroblasts in colitis and colorectal cancer. As a postdoctoral researcher he now seeks to understand the role of IL-17RA signalling in the progression of colorectal cancer.
Adele Nicolas completed her Bachelor of Science in General Biology at Notre Dame University Louaize (Lebanon) in 2012. In summer 2014 she joined the German Cancer Center (DKFZ) as a research intern at Professor Tobias Dick`s laboratory and investigated the role of mitochondrial H2O2 in mTOR signaling. In 2016 she completed her Master of Science in Clinical Molecular Biology at the University of Balamand (Lebanon). In September 2016 she joined the laboratory of Professor Florian Greten as a PhD student. Her current research focuses on the role of cancer associated fibroblasts in invasive colorectal cancer.
Kathleen worked as a Research Assistant at Oregon Health & Science University in Portland Oregon (USA) for 12 years before joining the group already in Munich in 2012. She is responsible for pre-clinical studies.
Hana Kunkel joined the Greten lab in 2016 and is responsible for lab management.
Kilian studied medicine at the University of Heidelberg and received his degree in 2019. During his studies, he joined the translational surgical oncology research group of Prof. Martin Schneider at the Department of General, Visceral and Transplantation Surgery at Heidelberg University Hospital. There, he studied the role of HIF-Prolyl hydroxylases in the development of colitis-associated carcinoma. Kilian joined the Greten lab in September 2019 as a PhD candidate and is currently investigating into the role of cancer-associated fibroblasts as well as deubiquitinating enzymes in colorectal cancer.
Christin Danneil is responsible for the management of the mouse colony.
Dr. Fatih Ceteci
Dr. Fatih Ceteci studied biology and obtained his MSc degree in molecular biology from Uludag University (Turkey). In 2002, he started his PhD in Ulf Rapp's group at the Institute of MSZ in Wuerzburg. During his PhD, he focused on the role of MAPK signaling in murine lung cancer. In 2008, he obtained his PhD degree and continued to work as postdoctoral research scientist in the same laboratory at the Max-Planck-Institute in Martinsried. In 2012, he moved to Owen Sansom's lab as a senior postdoctoral fellow to perform research on colorectal cancer at the Beatson Institute for Cancer Research in Glasgow (UK). In December 2015, he joined the Greten lab as a staff scientist to continue working on human colorectal cancer.
Dr. Verawan Boonsanay-Michel
Dr. Verawan Boonsanay-Michel studied molecular biology at University of Lyon (France). In 2009, she started her PhD work in Prof. Thomas Braun’s group at the Max-Planck-Institute of Heart and Lung Research in Bad Nauheim. Her project focused on epigenetic mechanisms regulating the quiescent state of muscle stem cells and chromatin-base mechanisms contributing to the distinct stem cell states. After obtaining her PhD by end of 2013, she continued as a post-doctoral researcher in the same lab. In 2014, she joined the group of Prof. Reinhard Fässler at the Max-Planck-Institute for Biochemistry in Martinsried and further investigated the role of integrin-adhesome on mesenchymal tumor stem cell homing. In March 2017, she joined the Greten lab where her research focuses on the function of chromatin in driving aberrant transcription programs during metastasis of colon cancer.
Dr. Claire Conche
Dr. Claire Conche studied biology at the University Paul Sabatier in Toulouse (France). For her PhD, Claire investigated the regulation of T cell activation threshold in the laboratory of Drs. Alain Trautmann & Georges Bismuth at the Cochin Institute in Paris (France). She graduated in 2009 and then joined the laboratory of Dr. Karsten Sauer at The Scripps Research Institute in Jolla (USA). There she focused on in vivo studies on T cells (development and peripheral functions), hematopoietic stem cells and blood cancers. She joined the Greten’s lab in March 2017 where she studies interactions between the immune and intestinal compartments.
Dr. Yasamin Dabiri
Dr. Yasamin Dabiri trained as a pharmacist in Tehran (Iran). In 2015, she came to Heidelberg University as a guest student, shortly after which she started her PhD at the Institute of Pharmacy and Molecular Biotechnology (IPMB) at Heidelberg University. During her PhD, she focused on developing new chemical approaches for modulation of key signaling pathways in tumorigenesis and stemness. She joined Prof. Dr. Florian Greten's lab in August 2020 where she is studying mechanisms of colorectal cancer cellular plasticity and metastasis.
Dr. Dominic Denk
Dr. Dominic Denk studied medicine at Goethe University in Frankfurt, obtaining his medical degree in 2019. For his thesis, he worked in the lab of Prof. Dr. Dr. Piiper at the Department of Internal Medicine I at University Hospital Frankfurt, studying the role of tumor-penetrating peptides in improving serum marker based diagnosis in translational models of hepatocellular carcinoma. He continues working at the Department of Internal Medicine I as a physician. As a clinician scientist, Dominic joined the Greten lab in 2021, focusing on immune-mediated antitumor responses in colorectal cancer. .
Esther Engel studied Biology at the Leibniz University Hannover and received her diploma in 2007. After that she worked for several institutes, especially focusing on in vivo models. Since September 2019 she joined the Greten lab funded by the LOEWE Center Frankfurt Cancer Institute examining therapy response of rectal cancer patients.
Luisa-Marie Pfeifer completed her Master of Science in Biomolecular Engineering at the Technical University Darmstadt. She conducted her master studies within the Department of ADCs & Targeted NBE Therapeutics at Merck Healthcare, where she developed in vitro co-culture assays to study immunomodulatory ADC´s mode of action in the field of immuno-oncology. Luisa joined the Greten lab as a PhD candidate in June 2021 as a member of the International Max Planck Research School (IMPRS) for Molecular Organ Biology and is currently working on elucidating novel targets for immunotherapy of colorectal cancer.